Immune checkpoint inhibitor therapy has shown excellent efficacy for tumor treatment; nonetheless, recent studies have shown that programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA4) blockades for the treatment of metastatic UM are ineffective (32). Here, CTLA4 is linked to neoplasm.